The impact of HLA-G polymorphisms on efficacy and toxicity in stage II-III CRC patients treated with adjuvant fluoropyrimidine-based chemotherapy and also in patients with non-metastatic CRC treated with the FOLFOX4 regimen (folinic acid/5-fluorouracil/oxaliplatin) has been reported previously [23,24]. Here, HLA-G is linked to colorectal carcinoma.